# 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis 

Dorothea Puchstein ${ }^{1}$ Felix Kork ${ }^{1}$ Herbert Schöchl ${ }^{2}$ Farahnaz Rayatdoost ${ }^{1}$ Oliver Grottke ${ }^{1}$

[^0]Address for correspondence Oliver Grottke, MD, PhD, MScPH,
Department of Anaesthesiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany
(e-mail: ogrottke@ukaachen.de).

Thromb Haemost 2023;123:40-53.


#### Abstract

\section*{Keywords} - anticoagulants - coagulopathy - prothrombin complex concentrates - vitamin K antagonists

Long-term anticoagulation is used worldwide to prevent or treat thrombotic events. Anticoagulant therapy using vitamin K antagonists (VKAs) is well established; however, anticoagulants carry an increased risk of potentially life-threatening bleeding. In cases of bleeding or need for surgery, patients require careful management, balancing the need for rapid anticoagulant reversal with risk of thromboembolic events. Prothrombin complex concentrates (PCCs) replenish clotting factors and reverse VKA-associated coagulopathy. Two forms of PCC, 3-factor (3F-PCC) and 4-factor (4F-PCC), are available. Using PRISMA methodology, we systematically reviewed whether 4F-PCC is superior to 3F-PCC for the reversal of VKA-associated coagulopathy. Of the 392 articles identified, 48 full texts were reviewed, with 11 articles identified using criteria based on the PICOS format. Data were captured from 1,155 patients: $3 F-P C C, n=651$; 4F-PCC, $n=504$. ROBINS-I was used to assess bias. Nine studies showed international normalized ratio (INR) normalization to a predefined goal, ranging from $\leq 1.5$ to $\leq 1.3$, following PCC treatment. Meta-analysis of the data showed that 4F-PCC was favorable compared with $3 F-P C C$ overall (odds ratio [OR]: 3.50; 95\% confidence interval [CI]: 1.88-6.52, $p<0.0001$ ) and for patients with a goal INR of $\leq 1.5$ or $\leq 1.3$ (OR: $3.45 ; 95 \% \mathrm{Cl}$ : $1.42-8.39, p=0.006$; OR: 3.25 ; $95 \% \mathrm{Cl}: 1.30-8.13, p=0.01$, respectively). However, heterogeneity was substantial $\left(I^{2}=62 \%, I^{2}=70 \%, I^{2}=64 \%\right)$. Neither a significant difference in mortality (OR: 0.72 ; $95 \% \mathrm{Cl}: 0.42-1.24, p=0.23$ ) nor in thromboembolisms was reported. These data suggest that $4 \mathrm{~F}-\mathrm{PCC}$ is better suited than $3 \mathrm{~F}-\mathrm{PCC}$ for the treatment of patients with VKA-associated coagulopathy, but further work is required for a definitive recommendation.


## received

August 9, 2022
accepted after revision
September 23, 2022

DOI https://doi.org/
10.1055/s-0042-1758653. ISSN 0340-6245.

[^1]

Visual summary. 3F-PCC vs. 4F-PCC for the reversal of VKA- associated coagulopathy. VKA: Vitamin K antagonists; VK: Vitamin K; VKOR: Vitamin K epoxide reductase; 4F-PCC: 4 -factor Prothrombin Complex Concentrate; 3F-PCC: 3-factor Prothrombin Complex Concentrate; II: factor II; VII: factor VII; IX: factor IX; X: factor X; INR: International Normalized Ratio.

## Introduction

Long-term anticoagulation is used worldwide to treat thrombotic events such as deep vein thrombosis and to prevent embolisms such as stroke from atrial fibrillation. ${ }^{1}$ Most patients take oral anticoagulants that either directly inhibit coagulation factors (direct oral anticoagulants [DOACs]) or that inhibit the formation of vitamin K-dependent coagulation factors II, VII, IX, and X (vitamin K antagonists [VKAs]). ${ }^{2}$ Although the use of newer DOACs is increasing, VKAs are often preferred based on comorbidities, the reason for anticoagulation and availability. ${ }^{1}$

By its very nature, all treatments with anticoagulants are associated with an increased risk of bleeding, with the risk of major bleeding for VKA therapy reported to be around 4 to $7 \%$ per patient-year. ${ }^{3-6}$ Bleeding in patients with coagulopathy is potentially life-threatening and can lead to severe disability. In cases of planned interventions, VKA medication can be paused or vitamin K can be substituted as clinically needed. However, some conditions such as lifethreatening bleeding or need for immediate surgery may require reversal of VKA therapy while at the same time balancing the risks of thromboembolic events. ${ }^{1}$ While direct antagonists for DOAC are available, rapid reversal of coagulopathy associated with VKA relies on substitution of the affected clotting factors. In practice, this can be achieved using fresh frozen plasma (FFP) or prothrombin complex concentrates (PCCs). ${ }^{7}$

PCCs are plasma-derived mixtures of clotting factors II, VII, IX, and $X$ in varying concentrations. Dosage is typically defined by the amount of factor IX in International Units (IU). Depending on the amount of factor VII, PCC can be categorized as either 3 -factor PCC (3F-PCC) or 4 -factor PCC (4F-PCC). ${ }^{8}$ - Table 1 shows the composition of different products.

A systematic review by Chai-Adisaksopha et al analyzing the data of 2,114 patients in 13 studies has already demonstrated PCC to be superior to FFP for the reversal of VKAassociated coagulopathy. ${ }^{9}$ Pathophysiological considerations suggest 4F-PCC to be more effective in comparison to $3 \mathrm{~F}-\mathrm{PCC}$ for the reversal of VKA-associated coagulopathy and some consensus guidelines recommend its preferred use. ${ }^{10,11}$ However, at present, there are only limited empirical data to support this practice.

In this systematic review and meta-analysis, we investigated whether 4F-PCC is superior to $3 \mathrm{~F}-\mathrm{PCC}$ for the reversal of VKA-associated coagulopathy.

## Methods

## Search Strategy

The search strategy was constructed following recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline. ${ }^{12}$ A search of five electronic databases (Medline, Cochrane Library, Web of Science, ClinicalTrials.gov, and EU Clinical Trials Register) from inception to February 18, 2022 was

Table 1 Concentration (in international units) of coagulation factors per 500 unit PCC, 3-factor (3F), and 4-factor (4F)

|  | Factor II | Factor VII | Factor IX | Factor X | Protein C | Protein S | Heparin <br> (IU/IU FIX) | Antithrombin |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Bebulin <br>  <br> $(3 F$, discontinued <br> in 2018) | 500 | $<25$ | 500 | 500 |  |  | $<0.15$ |  |
| Profiline SD (3F) |  | $\leq 750$ | $\leq 175$ | 500 | $\leq 500$ |  |  | 0 |
| Beriplex (4F) $)^{44}$ | $400-960$ | $200-500$ | $400-620$ | $440-1,200$ | $300-900$ | $240-760$ | $0.2-0.5$ | $5-15$ |
| Octaplex (4F) $)^{42}$ | $280-760$ | $180-480$ | 500 | $360-600$ | $260-620$ | $240-640$ | $0.2-0.5$ | 0 |
| Cofact (4F) ${ }^{42}$ | $280-700$ | $140-400$ | 500 | $280-700$ | $22-780$ | $20-160$ | 0 | $<0.6$ IU $/ \mathrm{mL}$ |

Abbreviations: FIX, factor IX; IU, international units.
conducted. Search terms were ""PCC" AND "vitamin K"" and ""PCC" AND " 3 -factor" AND " 4 -factor"" and no language restrictions were applied. Furthermore, the references of papers included in full-text screening were searched for other studies eligible for inclusion.

The inclusion criteria were constructed around the PICOS tool from the Cochrane Handbook for Systematic Reviews of Interventions. ${ }^{13}$ Studies were included if patients with VKAassociated coagulopathy ( P ) were treated with either 4F-PCC (Intervention, I) or 3F-PCC (Control, C). Outcomes (O) were reversal of anticoagulation measured using international normalized ratio (INR), mortality, thromboembolisms (TEs), and transfusion of further blood products. All study types (S) were included. Two reviewers (D.P. and F.R.) screened titles and abstracts. Cases of doubt about inclusion of full-text screened papers were resolved by discussion with a third reviewer (O.G.).

Study quality was evaluated by two reviewers (O.G. and D.P.) using the ROBINS-I assessment tool (Risk Of Bias In Nonrandomized Studies of Interventions). ${ }^{14}$ Because of the small number of studies meeting inclusion criteria, a formal assessment of the risk of publication bias was not performed.

## Statistical Analysis

For dichotomous outcomes including both-armed zeroevent studies, risk difference (RD) with $95 \%$ confidence intervals (CIs) was chosen as an effect measure. For all other dichotomous outcomes, the inverse-variance-weighted odds ratio (OR) with $95 \% \mathrm{Cl}$ was determined. For continuous outcomes, mean difference with $95 \% \mathrm{Cl}$ was calculated.

Heterogeneity between pooled studies was evaluated using the $I^{2}$ statistic. ${ }^{15}$ Heterogeneity was considered as low when $I^{2}$ was $\leq 35 \%$, moderate when $I^{2}$ was 36 to $60 \%$, and substantial when $I^{2}$ was $>60 \%$.

A random-effects model was used for all analyses. If only a median value was reported, the mean and standard deviation (SD) were calculated using the formulas described by Hozo et al and Wan et al. ${ }^{16,17}$ If only mean difference without SD was reported, SD was calculated via the $p$-value and sample size, as suggested in the Cochrane Handbook. ${ }^{13}$ Results were considered statistically significant if the $p$-value was $\leq 0.05$. Results were rounded to the second decimal place. Statistical analysis was conducted using Review Manager 5.4 and statistical software R 3.6.3 including the pwr package.

## Results

## Studies and Patients

In total, 425 articles were identified through the electronic search strategy. Review of references and expert recommendations identified a further 27 articles. After the removal of duplicates, 392 articles were screened by title and abstract. Overall, 48 articles were retained for full-text review. Of these, a total of 11 studies met the inclusion criteria, all of which were retrospective cohort studies. ${ }^{18-28}$ Three of these studies either compared PCC with other treatments (Wanek et al), or were for more than one indication (Mangram et al, Mohan et al), and only reported data on the comparison of $3 \mathrm{~F}-\mathrm{PCC}$ versus $4 \mathrm{~F}-\mathrm{PCC}$ for the reversal of VKA-associated coagulopathy in subgroup analyses. ${ }^{24,26,28}$ The study selection process is presented in $\mathbf{-}$ Fig. 1. In total, the data of 1,155 patients were included: 651 in the 3F-PCC group, and 504 in the $4 \mathrm{~F}-\mathrm{PCC}$ group. Characteristics of the included studies are summarized in - Table 2.

## Risk of Bias

The detailed risk of bias (RoB) assessment is presented in - Table 3. All studies had at least one serious RoB due to


Fig. 1 Flow chart describing the study selection process. PCC, prothrombin complex concentrate; rFVIIa, activated recombinant factor VII; VKA, vitamin K antagonist.
Table 2 Characteristics of included studies

|  | Number of patients | PCC used | Indication for reversal of anticoagulation | Intervention groups | PCC dose (units/kg) | Baseline INR | Time to repeat INR | Recruiting centers | Study period | Outcomes included in synthesis |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Voils et al, 2015 | 165 | Profiline vs. Kcentra | Intracranial hemorrhage (60\%) Gastrointestinal hemorrhage (10.30\%) Other (29.70\%) | 3F-PCC vs. 4F-PCC | $\begin{aligned} & \text { 3F-PCC: } 28(25-31)^{\mathrm{a}} \\ & \text { 4F-PCC: } 27(24-31)^{\mathrm{a}} \end{aligned}$ | 3F-PCC: <br> $2.5(2.0-3.2)^{a}$ <br> 4F-PCC: <br> $2.4(2.0-4.2)^{a}$ | All measurements within 30 minutes | Single center (United States) | 12/2011-7/2014 | Thromboembolisms In-hospital mortality Goal INR $\leq 1.5$ Mean change in INR |
| Al-Majzoub et al, 2016 | 53 | Profiline Kcentra | Intracranial <br> hemorrhage <br> (73.58\%) <br> Gastrointestinal <br> hemorrhage <br> (16.98\%) <br> Other hemorrhage <br> (9.43\%) | 3F-PCC vs. 4F-PCC | 3F-PCC: 25.5 (4.3) ${ }^{\text {b }}$ 4F-PCC: 27.9 (6.9) ${ }^{\text {b }}$ | $\begin{aligned} & \text { 3F-PCC: } 2.3(0.6)^{b} \\ & \text { 4F-PCC: } 3(1.5)^{b} \end{aligned}$ | $\begin{aligned} & \text { 3F-PCC: } 5 \mathrm{~h}(7.4 \mathrm{~h})^{\mathrm{b}} \\ & 4 \mathrm{~F}-\mathrm{PCC}: 3.7 \mathrm{~h}(4 \mathrm{~h})^{\mathrm{b}} \end{aligned}$ | Brigham and Women's Hospital, Boston (United States) | 3F- PCC: 8/2012-1/2013 4F-PCC: 8/2013-1/2014 | Thromboembolisms In-hospital mortality Goal INR $\leq 1.3$ Mean change in INR Mean post-PCC INR |
| Jones et al, <br> 2016 | 148 | Bebulin vs. Kcentra | Intracranial hemorrhage (81.08\%) Gastrointestinal hemorrhage (8.78\%) Other (10.14\%) | 3F-PCC vs. 4F-PCC | $\begin{aligned} & \begin{array}{l} \text { FF-PCC: } 30.6(28.2- \\ \text { F2.3): } \\ \text { FF-PCCC: } 26.3(24.7- \\ 34.3)^{2} \end{array} . \end{aligned}$ | 3F-PCC: <br> 2.6 (2.2.-3.5) ${ }^{\text {a }}$ <br> 4F-PCC: <br> $3.0(2.2-4.6)^{a}$ | 3F-PCC: <br> 48.59 minutes <br> (31.00- <br> 91.00 minutes $)^{\text {a }}$ <br> 4F-PCC: <br> 23.40 minutes <br> (15.33- <br> 90.00 minutes $)^{\text {a }}$ | 3F-PCC: Methodist University Hospital Memphis <br> (United States) 4F-PCC: University of Florida Health, University of Kentucky HealthCare, Temple University Hospital (United States) | Date of discharge: <br> 01.01.2012- <br> 15.04.2015 | Thromboembolisms In-hospital mortality Goal INR $\leq 1.4$ Mean post-PCC INR |
| Mangram et al, 2016 | 61 <br> (plus 3 treated <br> with rivaroxaban, <br> 1 in $3 F-$ <br> 2 in 4F-group) | Bebulin vs. Kcentra | $\begin{aligned} & \text { Trauma patients } \\ & (100 \%) \end{aligned}$ | 3F-PCC vs. 4F-PCC for reversal of VKA or rivaroxaban | 3F-PCC: 29 (9) ${ }^{\text {b }}, 2$ nd dose for 9 (all 9 treated with VKA, 20\%) 4F-PCC: 26 (6) ${ }^{\text {b }}$ Dosing for entire cohort including patients treated with rivaroxaban | (Including patients treated with rivaroxaban) 3F-PCC: 3.1 (2.3) ${ }^{\text {b }}$ <br> 4F-PCC: 3.4 (3.7) ${ }^{\text {b }}$ | (Including patients treated with rivaroxaban) 3F-PCC: 3 h (0.6-16.5 h) 4F-PCC: 4.2 h (0.6-18.9 h) (not specified whether median with IQR or range) | 1 level-I trauma center, 1 level-III trauma center (United States) | 1/2010-10/2014 | Goal INR $\leq 1.4$ |
| DeAngelo et al, 2018 | 89 | Profiline vs. Kcentra | Surgery (47.19\%) <br> Intracranial <br> hemorrhage <br> (34.83\%) <br> Other bleeding <br> locations (17.98\%) | 3F-PCC vs. 4F-PCC | 3F-PCC: 25 (23- <br> 27) ${ }^{\text {a }}, 2$ nd dose for 10 <br> (17.54\%): 24 (12- <br> 28) ${ }^{\text {a }}$ <br> 4F-PCC: 23 (20-27) ${ }^{\text {a }}$ <br> 2nd dose for 5 <br> (15.63\%): 10 (10- <br> $10)^{a}$ | 3F-PCC: <br> $2.6(2.2-3.7)^{\text {a }}$ <br> 4F-PCC: <br> $2.6(2.0-3.4)^{\text {a }}$ | Number of patients with repeat INR within 6 hours: <br> 3F-PCC: 50/57 <br> 4F-PCC: 31/32 | 2 tertiary care centers affiliated with the University of Arizona (United States) | 2/2014-8/2015 <br> (change from <br> $3 \mathrm{~F}-\mathrm{PCC}$ to $4 \mathrm{~F}-\mathrm{PCC}$ in <br> early 2015) | Thromboembolisms In-hospital mortality Goal INR $\leq 1.5$ |
| Fischer et al, 2018 | 103 | Profiline vs. Kcentra | Intracranial hemorrhage ( $100 \%$ ) | 3F-PCC vs. 4F-PCC | 3F-PCC: 26 (20- <br> $41)^{\text {a }}, 2$ nd dose for 5 <br> (12.5\%) <br> 4F-PCC: 25 (23- <br> 29) ${ }^{\text {a }}, 2$ nd dose for 3 <br> (4.76\%) | 3F-PCC: <br> $2.8(2.3-3.7)^{\text {a }}$ <br> 4F-PCC: <br> $2.6(2.2-3.1)^{\text {a }}$ | n/a | Intermountain Health Care (System of 22 hospitals, United States) | 01.10.2013- <br> 31.08.2015 (Switch <br> to $4 \mathrm{~F}-\mathrm{PCC}$ in 2014) | Thromboembolisms In-hospital mortality Mean post-PCC INR |
| Kuroski and Young, 2017 | 137 <br> (6 in each group without follow-up INR) | Bebulin vs. Kcentra | Intracranial hemorrhage (74.45\%) Gastrointestinal | 3F-PCC vs. 4F-PCC | 3F-PCC: 28.9 (22.540.1) ${ }^{\text {c }}$ <br> 4F-PCC: 25 (12-50) | 3F-PCC: <br> 3.15 (1.6-19) ${ }^{\text {c }}$ <br> 4F-PCC: 3.1 (2-19) ${ }^{\text {c }}$ | Only reported for those with repeat INR within 8 hours: 3F-PCC: 191 minutes | Allegheny General Hospital, Pittsburgh (United States) | 3F- PCC: <br> 01.01.2013- <br> 31.05.20 <br> 4F-PCC: | Thromboembolisms In-hospital mortality Goal INR $\leq 1.5$ |

Table 2 (Continued)

|  | Number of patients | PCC used | Indication for reversal of anticoagulation | Intervention groups | PCC dose (units/kg) | Baseline INR | Time to repeat INR | Recruiting centers | Study period | Outcomes included in synthesis |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | hemorrhage (4.38\%) <br> Surgery (2.19\%) <br> Other (18.98\%) |  |  | (laboratory maximum: 19) | (195 minutes) ${ }^{\text {b }}$ 4F-PCC: 169 minutes (230 minutes) ${ }^{\text {b }}$ |  | $\begin{aligned} & \text { 01.06.2014- } \\ & 15.09 .2015 \end{aligned}$ | $\begin{aligned} & \text { Goal INR } \leq 1.3 \\ & \text { Mean post-PCC INR } \end{aligned}$ |
| Mohan et al, 2018 | 128 | Bebulin vs. Kcentra | Intracranial hemorrhage (35.16\%) Gastrointestinal hemorrhage (25.78\%) Other (39.06\%) | 3F-PCC vs. 4F-PCC for elevated $\mathrm{INR}^{\text {d }}$ | $\begin{aligned} & \text { 3F-PCC: } 40.99 \\ & (18.00)^{\text {b }} \\ & \text { 4F-PCC: } 32.22 \\ & (11.07)^{\text {b }} \end{aligned}$ | $\begin{aligned} & \text { 3F-PCC: } 4.64(2.88)^{\mathrm{b}} \\ & \text { 4F-PCC: } 4.54(3.45)^{\mathrm{b}} \end{aligned}$ | Reported for entire cohort: <br> 3 h (median) | 1 public and 1 private hospital (United States) | $\begin{aligned} & \text { 01.01.2012- } \\ & 01.07 .2015 \end{aligned}$ | Thromboembolisms Mean change in INR Mean post-PCC INR |
| Holt et al, $2018$ | 134 | n/a | Intracranial hemorrhage (52.99\%) Gastrointestinal hemorrhage (14.18\%) Other bleeding locations (32.84\%) | 3F-PCC vs. 4F-PCC | $\begin{aligned} & \text { 3F-PCC: } 24.6(9.3)^{\mathrm{b}} \text {, } \\ & \text { 2nd dose for } \\ & \text { 3 patients } \\ & \text { 4F-PCC: } 36.3(12.8)^{\mathrm{b}} \end{aligned}$ | 3F-PCC: 3.61 (2.3) ${ }^{\text {b }}$ 4F-PCC: 6.87 (2.3) ${ }^{\text {b }}$ (values as described in text, SD different in Table of Study data) | $\begin{aligned} & \text { 3F-PCC: } 3.8 \mathrm{~h} \\ & (0.12 \mathrm{~h})^{\mathrm{b}} \\ & 4 \mathrm{~F}-\mathrm{PCC} .3 .3 \mathrm{~h} \\ & (0.10 \mathrm{~h})^{\mathrm{b}} \end{aligned}$ | 5 hospitals (United States) | 5/2011-9/2014 | Thromboembolisms In-hospital mortality Goal INR $\leq 1.5$ Goal INR $\leq 1.3$ Mean post-PCC INR |
| Wanek <br> et al, 2019 | 57 | Profiline vs. Kcentra | Heart <br> transplantation <br> (100\%) | PCC vs. historical control without PCC ${ }^{\text {d }}$ | 3F-PCC: 19.2 (6.4) ${ }^{\text {b }}$, 2nd dose for 34 patients, further doses for 12 patients 4F-PCC: 14.2 (5.4) ${ }^{\text {b }}$, 2nd dose for 2 patients | Reported only for entire cohort: $2.44(0.57)^{\text {b }}$ | n/a | Single center (United States) | 7/2013-12/2016 (4F-PCC starting in 12/2015) | Thromboembolisms Goal INR $\leq 1.5$ |
| Margraf <br> et al, 2020 | 80 | Profiline vs. Kcentra | Intracranial hemorrhage (62.5\%) Gastrointestinal hemorrhage (15\%) Other bleeding locations (22.5\%) | 3F-PCC vs. 4F-PCC | 3F-PCC: 21.5 <br> (20.4-25.9) ${ }^{\text {a }}$ <br> 4F-PCC: 29.3 <br> (25.9-37.3) ${ }^{\text {a }}$ <br> (only patients <br> receiving 20-50 <br> units/kg included) | $\begin{aligned} & 3 F-P C C: 2.8 \\ & (2.1-4.1)^{\mathrm{a}} \\ & 4 \mathrm{~F}-\mathrm{PCC}: 3.7 \\ & (2.6-4.9)^{\mathrm{a}} \end{aligned}$ | 3F-PCC: 215 minutes (133.0326.0 minutes) ${ }^{\text {a }}$ 4F-PCC: 296 minutes (241.0483.0 minutes) ${ }^{\text {a }}$ | North Memorial Medical Center, Robbinsdale (United States) | $\begin{aligned} & \text { 29.08.2007- } \\ & 30.06 .2014 \end{aligned}$ | Thromboembolisms In-hospital mortality Goal INR $\leq 1.5$ Mean change in INR Mean post-PCC INR |

[^2]Table 3 Risk of bias (RoB) assessment

|  | Voils 2015 | Al-Majzoub 2016 | Jones 2016 | $\begin{aligned} & \text { Mangram } \\ & 2016 \end{aligned}$ | $\begin{aligned} & \text { DeAngelo } \\ & 2018 \end{aligned}$ | Fischer 2018 | $\begin{aligned} & \text { Kuroski } \\ & 2017 \end{aligned}$ | Mohan $2018$ | Wanek 2019 | Holt <br> 2018 | Margraf $2020$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Bias due to confounding | ++ | ++ | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ | ++ |
| Bias in selection of participants | - | - | - | - | - | - | - | - | - | - | - |
| Bias due to classification of interventions | - | - | - | - | - | - | - | - | - | - | - |
| Bias due to deviation from intended interventions | + | + | + | + | + | + | + | ++ | + | + | + |
| Bias in measurements of outcome | - | - | - | - | - | - | - | - | - | - | - |
| Bias due to missing data | - | - | + | - | + | - | - | - | - | - | - |
| Bias in selection of the reported result | + | + | + | + | + | + | + | + | + | + | + |

Note: " - ": low RoB, " + ": moderate RoB, " + +": serious RoB, " + + +": critical RoB.
confounding by transfusion of FFP and other blood products. Two studies, Wanek et al and Mohan et al, did not specify how many patients in each PCC subgroup received FFP. ${ }^{26,28}$ In the study by Wanek et al, $94.74 \%$ of all patients received FFP with the possible difference between groups being considered to pose a serious RoB, while the RoB due to confounding for the study by Mohan et al was considered to pose a critical risk as $21.88 \%$ of all patients received FFP. ${ }^{26,28}$ Mangram et al reported information about co-administration of blood products for the entire cohort, including patients treated with rivaroxaban. ${ }^{24}$ However, as $13.04 \%$ of patients in the 3F-PCC group received a mean of 0.4 units of FFP and no patients in the $4 \mathrm{~F}-\mathrm{PCC}$ group received FFP before measuring INR, the risk of confounding was considered serious but not critical. ${ }^{24}$ None of the studies followed a preregistered protocol concerning the selection of reported results. Three studies, DeAngelo et al, Jones et al, and Holt et al, showed moderate RoB due to missing patient data. ${ }^{19,21,22}$ The RoB assessment was the same for all outcomes.

## International Normalized Ratio Reversal

Nine studies reported on the number of patients in whom the predefined goal INR was reached. Seven studies reported INR at either first control (after PCC therapy) or within a predetermined timespan after administration of PCC. Four studies reported on the change from pre- to post-PCC INR.

The predefined goal INR was not identical in all studies, ranging from $\leq 1.5$ to $\leq 1.3$. Jones et al reported on a goal INR of $\leq 1.4$, while Mangram et al reported on a goal INR of $<1.5$. The data from these studies were pooled as the observed difference between INR values was considered clinically irrelevant by the authors. ${ }^{22,24}$

Kuroski and Young provided data for the goal INR of $\leq 1.5$ for all included patients and for the goal INR of $\leq 1.3$ for a subgroup excluding five patients from the $4 \mathrm{~F}-\mathrm{PCC}$ and four patients from the 3F-PCC group whose follow-up INR was not measured within 8 hours of PCC administration. ${ }^{23}$ Holt et al reported a goal INR of $\leq 1.3$ for all patients and a goal INR of $\leq 1.5$ for a subgroup excluding four patients from the $4 \mathrm{~F}-\mathrm{PCC}$ group whose weight at admission was not recorded. ${ }^{21}$

- Fig. $\mathbf{2 ( A , B )}$ shows the number of patients to reach the goal INR in each of the studies. 4F-PCC was shown to be favorable in comparison with 3F-PCC for patients with a goal INR ranging from $\leq 1.5$ to $\leq 1.3$. A statistically significant difference between patients receiving $4 \mathrm{~F}-\mathrm{PCC}$ and $3 \mathrm{~F}-\mathrm{PCC}$ overall (-Fig. 2A; OR: 3.50; 95\% CI: 1.88-6.52, $p<0.0001$ ) and for patients with a goal INR of $\leq 1.5$ and $\leq 1.3$ was observed (-Fig. 2B; OR: 3.45; 95\% CI: 1.42-8.39, $p=0.006$ and OR: 3.25 ; $95 \%$ CI: $1.30-8.13, p=0.01$, respectively). This difference was not statistically significant for the subgroup of patients with a goal of INR $\leq 1.4$ (OR: $2.30 ; 95 \% \mathrm{CI}: 0.94-5.65$, $p=0.07$ ). Heterogeneity overall and in the INR $\leq 1.5$ and INR $\leq 1.3$ subgroups was substantial ( $I^{2}=62 \%, I^{2}=70 \%$, and $I^{2}=64 \%$, respectively). A sensitivity analysis, excluding the data from the study by Wanek et al due to unclear comedication with FFP, ${ }^{28}$ was performed. The sensitivity analysis showed no relevant difference in outcome in the INR $\leq 1.5$ subgroup.
A

B


Fig. 2 (A) Number of patients reaching goal INR; studies in order of descending ratio of $3 \mathrm{~F}-\mathrm{PCC}$ group patients/4F-PCC group patients who received FFP (prior to control INR if reported). Inclusion of data for primary goal INR from studies reporting on more than one goal INR. (B) Number of patients reaching goal INR; studies in order of descending ratio of 3F-PCC group patients/4F-PCC group patients who received FFP (prior to control INR if reported). Inclusion of subgroup data from studies reporting on more than one goal INR. CI, confidence interval; FFP, fresh frozen plasma; INR, international normalized ratio; PCC, prothrombin complex concentrate.

Further to this, four studies reported mean change in INR (-Fig. 3). These studies showed a statistically significant pooled mean difference of 0.86 ( $95 \% \mathrm{CI}: 0.43-1.28$, $p<0.0001$ ) favoring 4F-PCC over 3F-PCC.

Additionally, seven studies reported the INR after PCC administration: INR after administration of $4 \mathrm{~F}-\mathrm{PCC}$ was -0.21 ( $95 \% \mathrm{CI}$ : $-0.31,-0.11, p<0.0001$ ) lower compared with the $3 \mathrm{~F}-\mathrm{PCC}$ group. Heterogeneity between studies was substantial ( $I^{2}=87 \%$ ), but six out of the seven studies reporting on mean post-PCC INR reached statistical significance (-Fig. 4).

## Mortality

All studies reported in-hospital mortality. However, the study by Mangram et al included patients on treatment with rivaroxaban and did not report mortality for the subgroup of patients treated with VKA. In that study, the mortality of the entire cohort was $4.35 \%$ (3F-PCC) and $11.11 \%$ (4F-PCC). ${ }^{24}$ The studies by Wanek et al and Mohan et al reported mortality only for the entire PCC group. ${ }^{26,28}$ The pooled data from the remaining eight studies showed no statistically significant difference between patients treated with 4F-PCC (OR: $0.72 ; 95 \%$ CI: $0.42-1.24, p=0.23$; - Fig. 5).

|  | 4F-PCC |  |  | 3F-PCC |  |  |  | Mean Difference <br> IV, Random, 95\% CI | Mean Difference <br> IV, Random, 95\% CI |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight |  |  |  |  |
| Al-Majzoub et al. 2016 | 1.8 | 1.5 | 18 | 0.9 | 0.5 | 35 | 35.3\% | 0.90 [0.19, 1.61] |  |  |  |
| Voils et al. 2015 (1) | 2.2 | 3.44 | 56 | 1.4 | 3.1 | 109 | 15.6\% | 0.80 [-0.27, 1.87] |  |  |  |
| Margraf et al. 2020 (2) | 2.27 | 1.66 | 23 | 1.23 | 1.06 | 57 | 33.4\% | 1.04 [0.31, 1.77] |  |  |  |
| Mohan et al. 2017 | 3.23 | 3.48 | 96 | 2.8 | 2.33 | 32 | 15.8\% | 0.43 [-0.64, 1.50] |  |  |  |
| Total (95\% CI) | 193 |  |  |  |  | 233 100.0\% |  | 0.86 [0.43, 1.28] |  |  |  |
| Heterogeneity: $\mathrm{Tau}^{2}=0.00 ; \mathrm{Chi}^{2}=0.88, \mathrm{df}=3(\mathrm{P}=0.83) ; \mathrm{I}^{2}=0 \%$ Test for overall effect: $\mathrm{Z}=3.97$ ( $\mathrm{P}<0.0001$ ) |  |  |  |  |  |  |  |  | $\stackrel{1}{-2}$ | $\frac{1}{-1}{ }_{0}^{1}$ | ${ }_{0}{ }_{\text {Favors }}{ }^{\text {4F-PCC }}$ |

Fig. 3 Mean change in INR (absolute value); studies in order of descending ratio of 3F-PCC group patients/4F-PCC group patients who received FFP (prior to control INR if reported). (1) SD calculated using p-value; (2) mean and SD calculated from median and IQR. CI, confidence interval; FFP, fresh frozen plasma; INR, international normalized ratio; IQR, interquartile range; PCC, prothrombin complex concentrate; SD, standard deviation.


Fig. 4 Mean post-PCC INR; studies in order of descending ratio of $3 \mathrm{~F}-\mathrm{PCC}$ group patients/4F-PCC group patients who received FFP (prior to control INR if reported). (1) Mean and SD calculated from median and range; (2) mean and SD calculated from median and IQR. CI, confidence interval; FFP, fresh frozen plasma; INR, international normalized ratio; IQR, interquartile range; PCC, prothrombin complex concentrate; SD, standard deviation.

| Study or Subgroup | 4F-PCC |  | 3F-PCC |  | Odds Ratio |  |  | Odds Ratio <br> IV, Random, 95\% CI |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Voils et al. 2015 | 5 | 56 | 34 | 109 | 13.2\% | 0.22 [0.08, 0.59] | 2015 |  | -®- |  |  |
| Al-Majzoub et al. 2016 | 1 | 18 | 4 | 35 | 4.6\% | 0.46 [0.05, 4.41] | 2016 |  |  |  |  |
| Jones et al. 2016 | 18 | 64 | 26 | 84 | 16.9\% | 0.87 [0.43, 1.78] | 2016 |  |  |  |  |
| Kuroski and Young 2017 | 13 | 69 | 24 | 68 | 16.0\% | 0.43 [0.19, 0.93] | 2017 |  |  |  |  |
| Fischer et al. 2017 | 18 | 63 | 8 | 40 | 13.8\% | 1.60 [0.62, 4.13] | 2017 |  |  |  |  |
| DeAngelo et al. 2018 | 2 | 32 | 11 | 57 | 8.0\% | 0.28 [0.06, 1.35] | 2018 |  |  |  |  |
| Holt et al. 2018 | 12 | 57 | 13 | 77 | 14.8\% | 1.31 [0.55, 3.14] | 2018 |  |  |  |  |
| Margraf et al. 2020 | 8 | 23 | 14 | 57 | 12.7\% | 1.64 [0.57, 4.68] | 2020 |  |  |  |  |
| Total (95\% CI) |  | 382 |  | 527 | 100.0\% | 0.72 [0.42, 1.24] |  |  |  |  |  |
| Total events | 77 |  | 134 |  |  |  |  |  |  |  |  |
| Heterogeneity: $\mathrm{Tau}^{2}=0.3$ Test for overall effect: $Z=$ | $\begin{aligned} & ; \mathrm{Chi}^{2}= \\ & 1.19(\mathrm{P}= \end{aligned}$ | $\begin{aligned} & 15.95, \\ & =0.23) \end{aligned}$ | $d f=7$ | $=0.0$ | 3); $I^{2}=5$ |  |  | 0.01 | $\begin{aligned} & 0.1 \\ & \text { vors 4F-PCC } \end{aligned}$ | $\frac{1}{10}$ | 100 |

Fig. 5 Mortality. CI, confidence interval; PCC, prothrombin complex concentrate.

## Thromboembolisms

All 11 studies reported the number of TEs. The study by Mangram et al reported data for the entire cohort, with seven events in the $3 \mathrm{~F}-\mathrm{PCC}$ group and zero in the $4 \mathrm{~F}-\mathrm{PCC}$ group ( 15.22 vs. $0 \%, p=0.177$ ). ${ }^{24}$ Pooled data from the remaining 10 studies did not show a statistically significant RD between groups (RD: $0.01 ; 95 \% \mathrm{CI}:-0.01,0.03, p=0.30 ;-$ Fig. 6). Furthermore, none of these studies individually reached statistical significance.

## Transfusion of Blood Products

- Table 4 summarizes the co-administration of blood products and other hemostatic agents. The number of patients receiving FFP varied between studies and groups, with some centers adopting local protocols recommending the co-ad-
ministration of FFP, while in other centers the decision was left to the physicians. ${ }^{18,23,27}$ Wanek et al, Mohan et al and Mangram et al reported transfusion of blood products for the entire cohort and not by subgroup. ${ }^{24,26,28}$ In only one study, Jones et al, did patients in the 4 F - PCC group receive more FFP than in the control group. ${ }^{22}$ There were no data on the indication regarding the transfusion of packed red blood cells, platelets, or cryoprecipitate, or on the use of antifibrinolytics or activated recombinant factor VII. Apart from one study in which all patients received vitamin $K$, and another study that did not report on its administration, all others reported at least slightly higher rates of treatment with vitamin K in the $4 \mathrm{~F}-\mathrm{PCC}$ groups. DeAngelo et al also reported on the use of desmopressin for two patients who were also taking antiplatelet medication. ${ }^{19}$


Fig. 6 Thromboembolisms. CI, confidence interval; PCC, prothrombin complex concentrate.

## Discussion

In this systematic review and meta-analysis, we present evidence that 4F-PCC is more effective for the rapid reversal of VKA-associated coagulopathy in comparison with 3F-PCC. This is demonstrable in terms of normalizing INR, while the risk of TE remains unaffected. There was no statistically significant reduction in mortality. Patients receiving 3FPCC received more FFP in comparison with those receiving $4 \mathrm{~F}-\mathrm{PCC}$. This is the first systematic review of studies directly comparing 3F-PCC with 4F-PCC for the reversal of VKAassociated coagulopathy on effectiveness and safety. All included studies reported not only laboratory findings but also clinical outcomes such as mortality and occurrence of TE.

A systematic review by Voils and Baird investigated whether $4 \mathrm{~F}-\mathrm{PCC}$ was superior to $3 \mathrm{~F}-\mathrm{PCC} .{ }^{29}$ That review included data from studies evaluating the effect of either $3 \mathrm{~F}-\mathrm{PCC}$ or $4 \mathrm{~F}-\mathrm{PCC}$, but with no direct comparison of $3 \mathrm{~F}-\mathrm{PCC}$ versus $4 \mathrm{~F}-\mathrm{PCC}$ at the same study center. The authors found $4 \mathrm{~F}-\mathrm{PCC}$ to cause a more consistent decrease in INR, and repeated INR measurements were reported within a clearly defined timespan in most of the included studies. ${ }^{29}$ In the present analysis, varying time intervals between administration of PCC and repeat INR may have influenced the results due to differing half-lives of coagulation factors. ${ }^{7}$ However, clinical outcomes such as mortality and TE were not reported in the review performed by Voils and Baird, thus limiting the possibility for practical application of the results. ${ }^{29}$

The studies included in this review utilized INR as a marker to assess reversal of anticoagulation. 4F-PCC was shown to be favorable overall and for patients with a goal INR of $\leq 1.5$ and $\leq 1.3$ ( - Fig. 2a, b) in comparison with 3F-PCC. However, INR variability is an important consideration when interpreting these results. ${ }^{30-32}$ Not all authors reported when repeat INR measurements were taken and, due to the short half-life of factor VII, a late measure of INR could underestimate the initial effect of higher concentrations of factor VII in $4 \mathrm{~F}-\mathrm{PCC}$. Conversely, an early measurement may show adequate but not lasting reversal of anticoagulation when using $3 \mathrm{~F}-\mathrm{PCC} .{ }^{30-32}$

Another important consideration is that there is no consensus regarding the ideal threshold of INR to prevent
bleeding progression. In the studies presented herein, the goal INR value ranged from $\leq 1.5$ to $\leq 1.3$. INR as a standardized prothrombin time (PT) ratio can also be unevenly influenced by substituted factors: factor IX has no relevant influence on PT, and whether factor II, VII, or X has the greatest influence on INR is not definitively proven. ${ }^{30-32}$ Measuring the concentration of individual factors may be a more precise measure; however, these tests are not as readily available and may have a longer turnaround time. Moreover, recommendations on reversal goals based on individual factors would lack empirical basis. Furthermore, despite efforts to standardize results of PT through the introduction of INR, results from different laboratories do not always correlate well, further complicating the interpretation of results and limiting their practical value. ${ }^{33,34}$

TE rates remained consistent in patients treated with $4 \mathrm{~F}-$ PCC versus those treated with 3F-PCC. Similar rates of TE suggest that $4 \mathrm{~F}-\mathrm{PCC}$ is no more thrombogenic than $3 \mathrm{~F}-\mathrm{PCC}$. None of the studies reported a systematic screening for TE in all patients; therefore, it is likely that the true rate of TE is higher than those reported. Indeed, the pooled incidence of TE for each group ( $4.29 \%$ for $3 F-\mathrm{PCC}, 5.74 \%$ for $4 \mathrm{~F}-\mathrm{PCC}$ ) was slightly lower than reported in studies on single PCC products ( $6.77-10 \%$ for $3 \mathrm{~F}-\mathrm{PCC},{ }^{35,36} 6.81-7.77 \%$ for $4 \mathrm{~F}-\mathrm{PCC}^{37,38}$ ). However, as no studies reported a systematic screening for TE it is reasonable to expect similar rates of under-detection in both groups.

The studies analyzed in this review also showed that treatment with 4F-PCC was not associated with a statistically significant reduction in mortality (-Fig. 5). This finding is not surprising, as a normalization of the INR has not been shown to correlate with a reduction in mortality, which is also explained by the innumerable confounders influencing mortality. ${ }^{39,40}$ Also, the difference in resulting INR following $4 \mathrm{~F}-\mathrm{PCC}$ versus $3 \mathrm{~F}-\mathrm{PCC}$ treatment was too small ( - Fig. 4), to show a clinical impact.

Besides the heterogeneity of studies, especially the serious RoB due to confounding caused by co-medication could bias our results in either direction. Without prospective studies controlling for co-medication, the effect of this bias cannot be estimated exactly. As there was no difference in thromboembolic complications between the $3 \mathrm{~F}-\mathrm{PCC}$ and 4 F -
Table 4 Use of blood products and other hemostatic agents

|  | FFP ${ }^{\text {a }}$ | Vitamin $K^{\text {a }}$ | Recombinant factor VIla ${ }^{a}$ | Cryoprecipitate ${ }^{\text {a }}$ | Platelets ${ }^{\text {a }}$ | pRBC ${ }^{\text {a }}$ | Others ${ }^{\text {a }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Voils et al, 2015 | 3F-PCC: 80.73\% (median 2 units) ${ }^{\text {b }}$ 4F-PCC: 25\% (median 2 units) | $\begin{aligned} & \hline \text { 3F-PCC: } \\ & 91.74 \% \\ & 4 \mathrm{~F}-\mathrm{PCC:} \\ & 94.64 \% \end{aligned}$ |  |  |  |  |  |
| Al-Majzoub et al, 2016 (within 24h of PCC administration) | 3F-PCC: 60\% (3.66 units, SD 3.8) (2-3 units recommended by dosing protocol) <br> 4F-PCC: 16.67\% (1.7 units, SD 0.6) | $\begin{aligned} & \text { 3F-PCC: } \\ & \text { 77.14\% } \\ & \text { 4F-PCC: } \\ & 94.44 \% \end{aligned}$ |  |  | 3F-PCC: 45.71\% <br> (1.6 bags, SD 1) <br> 4F-PCC: 33.33\% <br> (0.65 bags, SD 1.5) | 3F-PCC: 25.71\% <br> (0.57 units, SD 1.2) <br> 4F-PCC: 27.78\% (0.6 <br> units, SD 1.2) |  |
| Jones et al, 2016 | 3F-PCC: $5.95 \%$ during hospital stay, 0 prior to repeat INR (median 2 units) 4F-PCC: $53.13 \%, 21.88 \%$ prior to repeat INR (median 2 units) | $\begin{aligned} & \hline \text { 3F-PCC: } \\ & \text { 90.48\% } \\ & \text { 4F-PCC: } \\ & 92.19 \% \end{aligned}$ |  |  |  |  |  |
| Mangram et al, 2016 ${ }^{\text {c }}$ | 3F-PCC: 13.04\% prior to PCC administration (mean 0.4 units, SD 1.2) 4F-PCC: 0 prior to PCC administration | $\begin{aligned} & \hline \text { 3F-PCC: } \\ & \text { 45.65\% } \\ & \text { 4F-PCC: } \\ & 66.67 \% \end{aligned}$ |  |  | 3F-PCC: n/a (mean 0.1 units, SD 0.4) 4F-PCC: n/a (mean 0.3 units, SD 0.7) | 3F-PCC: n/a (mean 0.4 units, SD 0.8) 4F-PCC: n/a (mean 0.8 units, SD 1.7) |  |
| DeAngelo et al, 2018 | 3F-PCC: 31.58\% (median: 612 mL , IQR 542-1136 mL) 4F-PCC: 28.13\% (median: 670 mL , IQR 546-918mL) | $\begin{aligned} & \text { 3F-PCC: } \\ & \text { 28.07\% } \\ & 4 \mathrm{~F}-\mathrm{PCC} \\ & 65.63 \% \mathrm{~d} \end{aligned}$ |  | 3F-PCC: 5.26\% (median: 229 mL , IQR 225-864mL) 4F-PCC: 12.5\% (median: 255 mL , IQR 149-578 mL) | 3F-PCC: 15.79\% (median: 296 mL , IQR 233-875 mL) 4F-PCC: 28.13\% (median: 817 mL , IQR 500-1,056 mL) | 3F-PCC: 36.84\% (median: 1039 mL , IQR 625-1,433 mL) 4F-PCC: 46.88\% (median: 625 mL , IQR 320-1705 mL) | Aminocaproic acid: 3F-PCC: $10.53 \%$ 4F-PCC: 21.88\% Desmopressin: 3F-PCC: 1.75\% 4F-PCC: $3.13 \%$ |
| Fischer et al, 2018 | 3F-PCC: 52.5\% <br> 4F-PCC: 26.98\% | $\begin{aligned} & \hline 3 F-P C C: \\ & 90 \% \\ & 4 F-P C C: \\ & 98.41 \% \end{aligned}$ |  |  |  |  |  |
| Kuroski and Young, 2017 | 3F-PCC: 60.29\% during hospital stay (median 3 units (range 1 15) ${ }^{\text {e }}, 47.06 \%$ prior to repeat INR 4F-PCC: $28.99 \%$ during hospital stay (median 2 units, range 2-10), 7.25\% prior to repeat INR | $\begin{aligned} & \text { 3F-PCC: } \\ & \text { 94.12\% } \\ & \text { 4F-PCC: } \\ & 98.55 \% \end{aligned}$ | $\begin{aligned} & \text { 3F-PCC: } 2.94 \% \\ & 4 \mathrm{~F}-\mathrm{PCC}: 0 \end{aligned}$ |  |  | 3F-PCC: 25\% (median 3 units, range 1-26 units) 4F-PCC: 18.84\% (median 2 units, range 1-5) |  |
| Mohan et al, 2018 ${ }^{\text {c }}$ (within 6h before or after PCC administration) | 21.88\% (mean 2.32 units) | 100\% |  |  | $\begin{aligned} & \text { 14.84\% } \\ & \text { (mean } 1.74 \text { units) } \end{aligned}$ | $\begin{aligned} & \text { 23.44\% } \\ & \text { (mean } 2.10 \text { units) } \end{aligned}$ |  |
| Holt et al, 2018 | 3F-PCC: 51.95\% <br> 4F-PCC: 17.54\% | $\begin{aligned} & \hline \text { 3F-PCC: } \\ & 90.91 \% \\ & 4 \mathrm{~F}-\mathrm{PCC} \\ & 96.49 \% \end{aligned}$ | $\begin{aligned} & \text { 3F-PCC: } 0 \\ & 4 \mathrm{~F}-\mathrm{PCC}: 1.75 \% \end{aligned}$ |  |  |  |  |

Table 4 (Continued)

|  | $\mathrm{FFP}^{\text {a }}$ | Vitamin $K^{a}$ | Recombinant factor VIIa ${ }^{\text {a }}$ | Cryoprecipitate ${ }^{\text {a }}$ | Platelets ${ }^{\text {a }}$ | pRBC ${ }^{\text {a }}$ | Others ${ }^{\text {a }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Wanek et al, 2019 ${ }^{\text {c }}$ | 94.74\% (median 6 units, IQR 4-8) | 98.25\% |  | $\begin{aligned} & \text { 73.68\% (median } 2 \\ & \text { units, IQR 2-4) } \end{aligned}$ | $100 \% \text { (median } 2$ units, IQR 1-3) | 87.72\% (median 7 units, IQR 4-11) | Aminocaproic acid: 56.14\% |
| Margraf et al, 2020 | 3F-PCC: 59.65\% (range 1-12 units) during hospital stay, $26.32 \%$ prior to repeat INR (range 1-4 units) 4F-PCC: 30.43\% (range 1-6 units) during hospital stay, $8.70 \%$ prior to repeat INR (range 1-2 units) | $\begin{aligned} & \hline \text { 3F-PCC: } \\ & \text { 85.96\% } \\ & \text { 4F-PCC: } \\ & 95.65 \% \end{aligned}$ | Exclusion criteria |  |  | $\begin{aligned} & \text { 3F-PCC: } 36.84 \% \\ & \text { (range } 1-12 \text { units) } \\ & \text { 4F-PCC: } 30.43 \% \\ & \text { (range } 1-4 \text { units) } \end{aligned}$ |  |

Abbreviations: FFP, fresh frozen plasma; IQR, interquartile range; pRBC, packed red blood cells; SD, standard deviation.
${ }^{\text {a Percentage of patients receiving product, dose if reported. }}$
${ }^{\text {d }}$ Prompt to administer vitamin K concurrently introduced in computer system with switch to 4F-PCC.
${ }^{\mathrm{e}} 2$ units recommended by dosing protocol if $\operatorname{INR} \geq 4$.

PCC groups, the additional procoagulative activity of 4F-PCC does not influence the occurrence of TE.

We cannot determine the probability of a type II error within the analysis. However, we can use our data to calculate a sample size for possible future studies comparing 4F-PCC and 3F-PCC toward mortality differences. Based on the mortality rates in both groups in our data, Cohen's h effect size for the difference between them is $0.13 .{ }^{41}$ This is a very small effect size, warranting the question whether this would be a clinically relevant effect to investigate. In fact, based on this effect size, the sample size needed for a significance level of 0.05 and a power of 0.80 would be $n=1,984$. However, because of the high relevance of the outcome to individual patients, it might still be useful to conduct further studies even if we expect only a statistically small effect.

Noteworthy was the heterogeneity of co-medication that patients received. All but one study with comparative data reported that patients receiving 3F-PCC were given more FFP in comparison with those receiving $4 \mathrm{~F}-\mathrm{PCC}$, possibly indicating that $3 \mathrm{~F}-\mathrm{PCC}$ requires supplementation to adequately reverse VKA-associated coagulopathy. ${ }^{22}$ Further, before the availability of 4F-PCC in the United States, physicians tended to transfuse FFP plus 3F-PCC to mimic the content of 4F-PCC and to increase factor VIIa levels.

However, the number of patients receiving blood products varied extensively between studies and groups, making interpretation of the data difficult. For instance, the administration of FFP varied from study to study, with several centers co-administering FFP alongside PCC as per local guidelines, while at other centers the decision was left to the physician. ${ }^{18,23,27}$ Of the nine studies reporting the dose of FFP, seven reported a mean or median dose of less than 4 units. ${ }^{18,19,22-24,26,27}$ The amount of factor VII in FFP may vary and therefore the effect of FFP in addition to 3F-PCC is hard to predict; however, taking into consideration that when PT is prolonged by $1 \%$ the recommended dose of FFP is $1 \mathrm{~mL} / \mathrm{kg}$, it is unlikely that this dose affected our findings. ${ }^{42}$

Vitamin K may also be administered to facilitate the reversal of VKA-associated coagulopathy. The rate of vitamin K administration, while above $90 \%$ in both groups for most centers, was also seen to vary from study to study, while factor VII was only administered in three patients in two studies. ${ }^{21,23}$

In the event that the goal INR was not reached and anticoagulation reversal was deemed inadequate, few authors reported on whether repeat doses of PCC were given or how patients were treated, further hampering interpretation of the data across studies. ${ }^{19-21,24,28}$ This might indicate that increased awareness of the physiology and pathophysiology of coagulation and anticoagulation and the relevant treatments is necessary in clinical practice.

## Limitations

Limitations of this review include the lack of randomized prospective studies and that every eligible study was conducted in the United States. However, the literature search and
screening strategy did not exclude randomized prospective studies or studies from outside the United States.

The substantial heterogeneity of study outcomes may at least in part be due to this lack of randomized prospective studies and poses a serious limitation in itself.

Another limitation was that some centers switched from $3 F-P C C$ to 4F-PCC as the new standard for the reversal of VKAassociated coagulopathy. ${ }^{18-20,23,28}$ It is unclear whether any other changes to guidelines or general treatment options might have influenced patient outcomes.

The only authors commenting on such a change were DeAngelo et al, who noted that a reminder to administer vitamin $K$ when ordering PCC was introduced to the electronic ordering system used at the study centers. As such, the difference in percentage of patients who received vitamin $K$ was highest in this study. ${ }^{19}$ Of note, the patients from the 4 F PCC group were significantly more likely to reach the goal INR of $\leq 1.5$ (OR: 8.35 ; $95 \%$ CI: 2.59-26.89; -Fig. 2b), a difference which exceeded the pooled OR of the subgroup (-Fig. 2b). Overall, fewer patients (from both groups) received vitamin K at these centers. Apart from two studies which did not provide comparative data on vitamin K administration, all others reported slightly higher rates of vitamin K use in the 4F-PCC groups ( - Table 4). Whether this was coincidence or caused by procedural changes, as described by DeAngelo et al, is unclear. However, a clear switch from one product to another eliminates the RoB by physicians choosing one treatment option over another for certain patients based on the assumed superiority of one. It is also noteworthy that none of the studies included patients treated after 2016, so even the centers that compared PCC products during the same treatment period might by now have switched due to the availability of $4 \mathrm{~F}-\mathrm{PCC}$ and its recommendation in consensus guidelines.

Finally, the mean or median doses of PCC were different for the two groups, with seven studies reporting a difference of more than $10 \%$ for the first dose of PCC, five with higher doses of 3F-PCC, ${ }^{22-24,26,28}$ and two with higher doses of 4FPCC. ${ }^{21,25}$ However, the patients from the 3F-PCC group reported on by Wanek et al (highest relative difference for higher doses of $3 \mathrm{~F}-\mathrm{PCC}$ ) and Mohan et al (highest total difference for higher doses of 3F-PCC) tended to more often fail to reach the goal INR (-Fig. 2a) or have lower post-PCC INR (-Fig. 4), respectively, than those from studies with more even doses. ${ }^{26,28}$

## Conclusion

The results of our meta-analysis show a statistically significant better INR normalization with 4F-PCC without any difference in thromboembolic complications. Our data support current recommendations and consensus guidelines ${ }^{10,11}$ to use 4F-PCC for VKA reversal. Further research is needed to define a consensus regarding the ideal, individualized degree of INR normalization required to achieve adequate reversal of anticoagulation to prevent bleeding progression. Besides, systematic screening for adverse effects and documentation of clinical indicators of
in vivo coagulation (i.e., bleeding cessation, blood loss during surgery) in future studies will help to generate results more applicable to real-world clinical settings.

## What is known about this topic?

- Bleeding in patients undergoing anticoagulant therapy can be life-threatening.
- Although use of newer direct oral anticoagulants (DOACs) is increasing, vitamin $K$ antagonists (VKAs) are still widely used. Prothrombin complex concentrates (PCCs) can be used to reverse coagulopathy associated with VKA therapy.
- PCC contains the vitamin K-dependent coagulation factors and is available in two forms, i.e., 3-factor (3F-PCC) or 4 -factor (4F-PCC); only 4F-PCC contains a significant amount of factor VII.


## What does this paper add?

- 4F-PCC is better suited for rapid reversal of VKAassociated coagulopathy in comparison with 3F-PCC.
- International normalized ratio normalization achieved via $4 \mathrm{~F}-\mathrm{PCC}$ treatment does not increase the risk of thromboembolism in comparison with $3 \mathrm{~F}-\mathrm{PCC}$.


## Funding

None.

## Conflict of Interest

O.G. has received research funding from Alexion, Bayer, Biotest, Boehringer Ingelheim, CSL Behring, Octapharma, Novo Nordisk, Nycomed, and Werfen. He has also received honoraria for lectures and consultancy support from Baxalta, Bayer AG, Boehringer Ingelheim, Ferring, CSL Behring, Octapharma, Pfizer, Takeda, Portola, and Sanofi. H.S. has received speaker fees from CSL Behring, TEM International, Haemonetics, and Stago.

## Acknowledgments

We acknowledge the Institute of Medical Statistics, RWTH Aachen, for providing statistical advice.

## References

1 Cosmi B. An update on the pharmaceutical management of thrombosis. Expert Opin Pharmacother 2016;17(16):2149-2164
2 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968-1975
3 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139(11): 893-900
4 Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6, Suppl):257S-298S

5 Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115(21):2689-2696
6 Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42(01):112-118
7 Levy JH, Ghadimi K, Waldron NH, Connors JM. Using plasma and prothrombin complex concentrates. Semin Thromb Hemost 2020;46(01):32-37
8 Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016;122 (05):1287-1300

9 Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016;116(05):879-890
10 Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018;2(22):3257-3291
11 Frontera JA, Lewin JJ III, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016;24(01):6-46
12 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906
13 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions, Version 6.2 (updated February 2021). Cochrane 2021. Available at: training.cochrane.org/handbook

14 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919
15 Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21(11):1539-1558
16 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13
17 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135
18 Al-Majzoub O, Rybak E, Reardon DP, Krause P, Connors JM. Evaluation of warfarin reversal with 4-factor prothrombin complex concentrate compared to 3-factor prothrombin complex concentrate at a tertiary academic medical center. J Emerg Med 2016;50(01):7-13
19 DeAngelo J, Jarrell D, Cosgrove R, Camamo J, Edwards C, Patanwala AE. Comparison of 3-factor versus 4-factor prothrombin complex concentrate with regard to warfarin reversal, blood product use, and costs. Am J Ther 2018;25(03):e326-e332
20 Fischer D, Sorensen J, Fontaine GV. Three-factor versus four-factor prothrombin complex concentrate for the emergent management of warfarin-associated intracranial hemorrhage. Neurocrit Care 2018;28(01):43-50
21 Holt T, Taylor S, Abraham P, et al. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarininduced bleeding. Int J Crit Illn Inj Sci 2018;8(01):36-40
22 Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L. 3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis 2016;42(01):19-26

23 Kuroski JE, Young S. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin. Am J Emerg Med 2017;35 (06):871-874

24 Mangram A, Oguntodu OF, Dzandu JK, et al. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4factor prothrombin complex concentrates among trauma patients on oral anticoagulants? J Crit Care 2016;33:252-256
25 Margraf DJ, Seaburg S, Beilman GJ, Wolfson J, Gipson JC, Chapman SA. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study. BMC Emerg Med 2020;20(01):93
26 Mohan S, Howland MA, Lugassy D, Jacobson J, Su MK. The use of 3and 4-factor prothrombin complex concentrate in patients with elevated INR. J Pharm Pract 2018;31(03):262-267
27 Voils SA, Holder MC, Premraj S, Catlin JR, Allen BR. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal. Thromb Res 2015;136(03): 595-598
28 Wanek MR, Hodges K, Persaud RA, et al. Prothrombin complex concentrates for warfarin reversal before heart transplantation. Ann Thorac Surg 2019;107(05):1409-1415
29 Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 2012;130(06):833-840
30 Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997;8(01):48-53
31 Watala C, Golanski J, Kardas P. Multivariate relationships between international normalized ratio and vitamin K-dependent coagu-lation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb J 2003;1(01):7
32 Weinstock DM, Chang P, Aronson DL, Kessler CM. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol 1998;57(03): 193-199
33 Horsti J, Uppa H, Vilpo JA. Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. Clin Chem 2005;51(03):553-560
34 Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of prothrombin time/international normalized ratio (PT/INR). Int J Lab Hematol 2021;43(01):21-28
35 Zweng I, Galvin S, Robbins R, et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart Lung Circ 2019;28(11): 1706-1713
36 Chapman SA, Irwin ED, Abou-Karam NM, et al. Comparison of 3factor prothrombin complex concentrate and low-dose recombinant factor VIIa for warfarin reversal. World J Emerg Surg 2014;9:27
37 Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4factor prothrombin complex concentrate in patients on vitamin $K$ antagonists presenting with major bleeding: a randomized, plas-ma-controlled, phase IIIb study. Circulation 2013;128(11): 1234-1243
38 Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin $K$ antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015;385(9982):2077-2087

39 Pan R, Cheng J, Lai K, Huang Q, Wu H, Tang Y. Efficacy and safety of prothrombin complex concentrate for vitamin $K$ antagonist-associated intracranial hemorrhage: a systematic review and metaanalysis. Neurol Sci 2019;40(04):813-827
40 Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4 -factor prothrombin complex concentrate for reversal of vitamin $K$ antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis 2017;44(01):118-129

41 Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates; 1988
42 Bauer F, Gary T, Gattringer T, et al. Gerinnung im klinischen Alltag. 8. Auflage edn. Graz: Interdisziplinäre Gerinnungsgruppe Steiermark; 2019
43 [Anonymous]. Package Insert - Profilnine® SD. 2010 ed. Silver Spring, MD: U.S. Food and Drug Administration;
44 (Anonymous). Fachinformation, CSL Behring Beriplex® P/N 250/500/ 1000. 2020, Rote Liste Service GmbH, Fachinfo-Service, Frankfurt


[^0]:    ${ }^{1}$ Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany
    ${ }^{2}$ Department for Anaesthesiology and Intensive Care Medicine, AUVA Trauma Academic Teaching Hospital, Paracelsus Medical University Salzburg, Salzburg, Austria

[^1]:    © 2023. The Author(s).
    This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/ licenses/by-nc-nd/4.0/)
    Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

[^2]:    Abbreviations: INR, international normalized ratio; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist. ${ }^{\text {a }}$ Median with $\operatorname{IQR}$ (interquartile range).
    ${ }^{\text {b }}$ Mean, SD (standard deviation).
    ${ }^{\text {c M M }}$ Median with range.
    ${ }^{\text {d }} 3 \mathrm{~F}$-PCC versus $4 \mathrm{~F}-\mathrm{PCC}$ for VKA reversal in subgroup analysis.

